Skip to main content
Clinical Trials/NCT04150458
NCT04150458
Enrolling By Invitation
Phase 3

Performance of 18F-Fluorocholine Positron Emission Tomography With Computed Tomography in Patients With 18F-Fluorocholine-avid Lesions: A Basket Trial

Sir Mortimer B. Davis - Jewish General Hospital1 site in 1 country2,000 target enrollmentNovember 30, 2022

Overview

Phase
Phase 3
Intervention
18F-fluorocholine PET/CT.
Conditions
Fluorocholine PET/CT
Sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Enrollment
2000
Locations
1
Primary Endpoint
Diagnostic accuracy of Fluorocholine PET/CT
Status
Enrolling By Invitation
Last Updated
2 years ago

Overview

Brief Summary

This is a single-arm, open-label, phase III trial in up to 2000 patients with known or suspected benign or malignant tumors which are known or suspected to be 18F-fluorocholine-avid.

Patients will receive regular standard clinical care. The only study-specific procedure will be the administration of 18F-fluorocholine followed by a PET/CT scan.

Diagnostic accuracy of 18F-fluorocholine PET/CT will be captured versus a composite clinical, radiological and histopathological standard of truth at follow-up.

Registry
clinicaltrials.gov
Start Date
November 30, 2022
End Date
July 2030
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Responsible Party
Principal Investigator
Principal Investigator

Stephan Probst, MD

Chief of Nuclear Medicine

Sir Mortimer B. Davis - Jewish General Hospital

Eligibility Criteria

Inclusion Criteria

  • Age 18 years or older
  • Under referring physician's care
  • Able to understand and provide written informed consent
  • Able to tolerate the physical/logistical requirements of a PET/CT scan including lying supine (or prone) for up to 30 minutes and tolerating intravenous cannulation for injection
  • Known or suspected benign or malignant tumor which is known or suspected to be 18F-fluorocholine-avid as per current medical literature

Exclusion Criteria

  • Medically unstable (e.g. acute cardiac or respiratory distress or hypotensive)
  • Exceeding the safe weight limit of the PET/CT bed (usually approximately 400 lbs.) or cannot fit through the PET/CT bore (usually approximately 70 cm diameter)
  • Unmanageable claustrophobia

Arms & Interventions

Fluorocholine PET/CT

The sole study-specific procedure is a single 18F-fluorocholine positron emission tomography / computed tomography (PET/CT). Subjects will receive 9 mCi 18F-fluorocholine IV, 5 to 120 minutes prior to PET/CT. 18F-fluorocholine PET/CT studies will be performed on hybrid PET/CT scanners which combine a dedicated, full-ring PET scanner with a multi-slice spiral CT scanner.

Intervention: 18F-fluorocholine PET/CT.

Outcomes

Primary Outcomes

Diagnostic accuracy of Fluorocholine PET/CT

Time Frame: 1 day

Sensitivity, specificity, positive predictive and negative predictive values of 18F-fluorocholine PET/CT in the detection of tumor lesions as compared to a composite truth standard.

Secondary Outcomes

  • Incidence of treatment-emergent adverse events following Fluorocholine PET/CT(30 minutes)

Study Sites (1)

Loading locations...

Similar Trials